Gland Pharma Ltd.
GLANDHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
22 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 22 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210210 | 2020-12-31 | yes | |
| TRANSCRIPT | 20210521 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210731 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211103 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220128 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220526 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220727 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221102 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230131 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230525 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230811 | 2023-06-30 | yes | |
| TRANSCRIPT | 20240221 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240529 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240812 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241111 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250210 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250527 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250811 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251107 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260203 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260520 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260817 | 2026-06-30 | yes |
GLAND
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 2,897.40 |
| 52-week range | 1596.8 – 3026.2 |
| Return 1M | 2.58% |
| Return 3M | 25.17% |
| Return 1Y | 46.5% |
| Return 3Y | 74.56% |
| Return 5Y | -24.63% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,800.00 |
| Other income | 61.00 |
| Total income | 1,861.00 |
| Cost of materials consumed | 588.00 |
| Purchases of stock-in-trade | 2.00 |
| Changes in inventories | 34.00 |
| Employee benefit expense | 444.00 |
| Finance costs | 4.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.52 | -0.00 |
| institutions foreign | 0.09 | 0.01 |
| institutions domestic | 0.30 | -0.03 |
| mutual funds | 0.28 | -0.04 |
| public | 0.48 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 22 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,044.00 | 938.00 | 785.00 | 1,209.00 | 1,373.00 | 1,545.00 | 1,537.00 | 1,402.00 | 1,406.00 | 1,384.00 | 1,425.00 | 1,506.00 | 1,487.00 | 1,695.00 | 1,743.00 | 1,800.00 |
| Other income | 66.00 | 62.00 | 39.00 | 38.00 | 53.00 | 37.00 | 42.00 | 51.00 | 60.00 | 58.00 | 44.00 | 58.00 | 84.00 | 63.00 | 111.00 | 61.00 |
| Total income | 1,110.00 | 1,000.00 | 824.00 | 1,246.00 | 1,427.00 | 1,583.00 | 1,580.00 | 1,453.00 | 1,465.00 | 1,443.00 | 1,469.00 | 1,563.00 | 1,571.00 | 1,759.00 | 1,854.00 | 1,861.00 |
| Cost of materials consumed | 504.00 | 433.00 | 438.00 | 466.00 | 518.00 | 464.00 | 575.00 | 462.00 | 486.00 | 437.00 | 588.00 | 557.00 | 558.00 | 530.00 | 594.00 | 588.00 |
| Purchases of stock-in-trade | 4.00 | 4.00 | 3.00 | 4.00 | 6.00 | 6.00 | 7.00 | 7.00 | 3.00 | 2.00 | 3.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Changes in inventories | 11.00 | -10.00 | -77.00 | -16.00 | -2.00 | 129.00 | 18.00 | 96.00 | 87.00 | 23.00 | -103.00 | -37.00 | -7.00 | 45.00 | -5.00 | 34.00 |
| Employee benefit expense | 101.00 | 101.00 | 103.00 | 255.00 | 305.00 | 345.00 | 352.00 | 356.00 | 330.00 | 343.00 | 373.00 | 408.00 | 385.00 | 424.00 | 412.00 | 444.00 |
| Finance costs | 2.00 | 3.00 | 2.00 | 5.00 | 6.00 | 5.00 | 10.00 | 6.00 | 6.00 | 23.00 | 7.00 | 11.00 | 8.00 | 4.00 | 10.00 | 4.00 |
| Depreciation and amortisation | 37.00 | 38.00 | 38.00 | 65.00 | 81.00 | 105.00 | 93.00 | 92.00 | 94.00 | 96.00 | 96.00 | 101.00 | 106.00 | 108.00 | 109.00 | 111.00 |
| Other expenses | 127.00 | 121.00 | 149.00 | 207.00 | 223.00 | 244.00 | 228.00 | 218.00 | 204.00 | 219.00 | 216.00 | 209.00 | 234.00 | 260.00 | 227.00 | 243.00 |
| Total expenses | 786.00 | 689.00 | 656.00 | 985.00 | 1,137.00 | 1,299.00 | 1,281.00 | 1,235.00 | 1,209.00 | 1,143.00 | 1,181.00 | 1,250.00 | 1,287.00 | 1,372.00 | 1,348.00 | 1,427.00 |
| Profit before exceptional items and tax | 324.00 | 311.00 | 168.00 | 261.00 | 290.00 | 283.00 | 298.00 | 218.00 | 257.00 | 299.00 | 288.00 | 313.00 | 284.00 | 386.00 | 506.00 | 435.00 |
| Exceptional items | 0.00 | 0.00 | -56.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.00 | 0.00 | 0.00 |
| Profit before tax | 324.00 | 311.00 | 111.00 | 261.00 | 290.00 | 283.00 | 298.00 | 218.00 | 257.00 | 299.00 | 288.00 | 313.00 | 284.00 | 362.00 | 506.00 | 435.00 |
| Current tax | 81.00 | 77.00 | 43.00 | 59.00 | 89.00 | 97.00 | 100.00 | 78.00 | 96.00 | 95.00 | 104.00 | 102.00 | 104.00 | 109.00 | 144.00 | 125.00 |
| Deferred tax | 2.00 | 2.00 | -10.00 | 8.00 | 7.00 | -6.00 | 6.00 | -3.00 | -3.00 | 0.00 | -2.00 | -5.00 | -4.00 | -8.00 | -5.00 | -7.00 |
| Tax expense | 83.00 | 79.00 | 32.00 | 67.00 | 96.00 | 91.00 | 106.00 | 74.00 | 93.00 | 95.00 | 102.00 | 97.00 | 100.00 | 101.00 | 139.00 | 118.00 |
| Profit for the period | 241.00 | 232.00 | 79.00 | 194.00 | 194.00 | 192.00 | 192.00 | 144.00 | 164.00 | 205.00 | 187.00 | 215.00 | 184.00 | 261.00 | 367.00 | 317.00 |
| Profit attributable to owners | 241.00 | 232.00 | 79.00 | 194.00 | 194.00 | 192.00 | 192.00 | 144.00 | 164.00 | 205.00 | 187.00 | 215.00 | 184.00 | 261.00 | 367.00 | 317.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 2.00 | 1.00 | -5.00 | -25.00 | -16.00 | 75.00 | -43.00 | -12.00 | 96.00 | -93.00 | 65.00 | 186.00 | 103.00 | 41.00 | 101.00 | -27.00 |
| Total comprehensive income | 243.00 | 233.00 | 74.00 | 169.00 | 178.00 | 267.00 | 150.00 | 132.00 | 260.00 | 111.00 | 251.00 | 402.00 | 287.00 | 302.00 | 468.00 | 290.00 |
| Earnings per share, basic | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.23 |
| Earnings per share, diluted | 14.65 | 14.08 | 4.78 | 11.78 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.23 | 19.22 |
Annual results, as filed
| Line | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Revenue from operations | 3,463.00 | 4,401.00 | 3,625.00 | 5,665.00 | 5,617.00 | 6,431.00 |
| Other income | 135.00 | 224.00 | 240.00 | 170.00 | 214.00 | 316.00 |
| Total income | 3,598.00 | 4,625.00 | 3,865.00 | 5,835.00 | 5,830.00 | 6,747.00 |
| Cost of materials consumed | 1,749.00 | 2,047.00 | 1,717.00 | 2,022.00 | 1,972.00 | 2,240.00 |
| Purchases of stock-in-trade | 16.00 | 26.00 | 16.00 | 23.00 | 14.00 | 7.00 |
| Changes in inventories | -273.00 | 37.00 | -47.00 | 128.00 | 103.00 | -3.00 |
| Employee benefit expense | 311.00 | 339.00 | 403.00 | 1,257.00 | 1,402.00 | 1,629.00 |
| Finance costs | 3.00 | 5.00 | 7.00 | 26.00 | 42.00 | 33.00 |
| Depreciation and amortisation | 99.00 | 110.00 | 147.00 | 345.00 | 378.00 | 424.00 |
| Other expenses | 357.00 | 443.00 | 511.00 | 902.00 | 856.00 | 929.00 |
| Total expenses | 2,263.00 | 3,006.00 | 2,754.00 | 4,702.00 | 4,767.00 | 5,258.00 |
| Profit before exceptional items and tax | 1,335.00 | 1,619.00 | 1,111.00 | 1,133.00 | 1,063.00 | 1,489.00 |
| Exceptional items | 0.00 | 0.00 | -56.00 | 0.00 | 0.00 | -24.00 |
| Profit before tax | 1,335.00 | 1,619.00 | 1,055.00 | 1,133.00 | 1,063.00 | 1,465.00 |
| Current tax | 338.00 | 393.00 | 276.00 | 346.00 | 372.00 | 459.00 |
| Deferred tax | 0.00 | 14.00 | -3.00 | 14.00 | -8.00 | -22.00 |
| Tax expense | 338.00 | 407.00 | 274.00 | 360.00 | 364.00 | 437.00 |
| Profit for the period | 997.00 | 1,212.00 | 781.00 | 772.00 | 699.00 | 1,027.00 |
| Profit attributable to owners | 997.00 | 1,212.00 | 781.00 | 772.00 | 699.00 | 1,027.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | -1.00 | -0.00 | -1.00 | -8.00 | 55.00 | 431.00 |
| Total comprehensive income | 996.00 | 1,211.00 | 780.00 | 765.00 | 754.00 | 1,458.00 |
| Earnings per share, basic | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 | 62.35 |
| Earnings per share, diluted | 62.99 | 73.64 | 47.43 | 46.89 | 42.40 | 62.28 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 8,621.00 | 8,778.00 | 10,293.00 | 10,661.00 | 10,867.00 | 11,225.00 | 11,800.00 | 12,511.00 |
| Non-current assets | 2,312.00 | 1,877.00 | 4,322.00 | 5,016.00 | 4,463.00 | 4,442.00 | 4,755.00 | 4,984.00 |
| Current assets | 6,309.00 | 6,901.00 | 5,971.00 | 5,645.00 | 6,404.00 | 6,783.00 | 7,045.00 | 7,527.00 |
| Property, plant and equipment | 1,553.00 | 1,559.00 | 3,050.00 | 3,541.00 | 3,610.00 | 3,751.00 | 3,965.00 | 4,052.00 |
| Capital work-in-progress | 125.00 | 177.00 | 320.00 | 238.00 | 277.00 | 151.00 | 209.00 | 342.00 |
| Goodwill | 0.00 | 0.00 | 456.00 | 242.00 | 253.00 | 248.00 | 281.00 | 294.00 |
| Other intangible assets | 2.00 | 12.00 | 154.00 | 112.00 | 112.00 | 106.00 | 112.00 | 109.00 |
| Inventories | 1,560.00 | 1,945.00 | 2,084.00 | 1,655.00 | 1,577.00 | 1,685.00 | 1,814.00 | 1,744.00 |
| Trade receivables | 1,201.00 | 871.00 | 1,373.00 | 1,559.00 | 1,490.00 | 1,517.00 | 1,565.00 | 1,891.00 |
| Cash and cash equivalents | 534.00 | 1,909.00 | 481.00 | 357.00 | 2,820.00 | 2,556.00 | 2,704.00 | 3,359.00 |
| Total equity and liabilities | 8,621.00 | 8,778.00 | 10,293.00 | 10,661.00 | 10,867.00 | 11,225.00 | 11,800.00 | 12,511.00 |
| Equity | 7,651.00 | 7,959.00 | 8,307.00 | 8,724.00 | 8,788.00 | 9,151.00 | 9,563.00 | 10,358.00 |
| Equity share capital | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 |
| Other equity | 7,635.00 | 7,942.00 | 8,290.00 | 8,707.00 | 8,772.00 | 9,134.00 | 9,546.00 | 10,341.00 |
| Total liabilities | 970.00 | 819.00 | 1,986.00 | 1,937.00 | 2,079.00 | 2,074.00 | 2,237.00 | 2,153.00 |
| Non-current liabilities | 100.00 | 90.00 | 450.00 | 539.00 | 540.00 | 509.00 | 531.00 | 544.00 |
| Current liabilities | 870.00 | 729.00 | 1,536.00 | 1,398.00 | 1,539.00 | 1,565.00 | 1,706.00 | 1,608.00 |
| Borrowings, non-current | 3.00 | 3.00 | 121.00 | 107.00 | 94.00 | 78.00 | 74.00 | 70.00 |
| Borrowings, current | 1.00 | 1.00 | 192.00 | 213.00 | 185.00 | 192.00 | 181.00 | 173.00 |
| Trade payables | 702.00 | 587.00 | 978.00 | 863.00 | 998.00 | 820.00 | 924.00 | 834.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 396.00 | 364.00 | 422.00 | 997.00 | 644.00 | 915.00 | 593.00 | 1,031.00 |
| Net cash from investing activities | -201.00 | 1,208.00 | -1,050.00 | -1,757.00 | 2,213.00 | 1,705.00 | -92.00 | 138.00 |
| Net cash from financing activities | 19.00 | 15.00 | -801.00 | -799.00 | -403.00 | -433.00 | -379.00 | -417.00 |
| Purchase of property, plant and equipment | 82.00 | 221.00 | 161.00 | 390.00 | 157.00 | 385.00 | 194.00 | 491.00 |
| Net increase in cash | 215.00 | 1,590.00 | -1,428.00 | -1,552.00 | 2,463.00 | 2,199.00 | 148.00 | 803.00 |
| con:CFO.BEFORE_TAX | 530.00 | 675.00 | 531.00 | 1,303.00 | 767.00 | 1,269.00 | 776.00 | 1,487.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 134.00 | 311.00 | 110.00 | 306.00 | 123.00 | 354.00 | 182.00 | 455.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 1,022.00 | 1,022.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 57.86 | 57.86 | 57.86 | 57.86 | 57.86 | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 | 0.52 | 0.52 | 0.52 | 0.52 |
| Domestic institutions | 23.23 | 23.38 | 22.45 | 24.17 | 25.23 | 32.83 | 35.37 | 34.80 | 33.27 | 32.85 | 0.33 | 0.33 | 0.33 | 0.30 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 30.67 | 0.30 | 0.31 | 0.32 | 0.28 |
| Insurance companies | 2.02 | 1.80 | 1.79 | 1.80 | 1.21 | 1.29 | 1.50 | 1.38 | 1.32 | 1.27 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 4.33 | 2.80 | 4.91 | 4.04 | 3.59 | 6.88 | 4.47 | 5.04 | 6.90 | 7.39 | 0.08 | 0.08 | 0.07 | 0.09 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 42.14 | 42.14 | 42.14 | 42.14 | 42.14 | 48.17 | 48.17 | 48.17 | 48.17 | 48.17 | 0.48 | 0.48 | 0.48 | 0.48 |
| Non-institutional | 14.58 | 15.96 | 14.78 | 13.93 | 13.32 | 8.45 | 8.32 | 8.33 | 7.99 | 7.93 | 0.08 | 0.08 | 0.08 | 0.09 |
| Shares outstanding | 164700823 | 164700823 | 164700823 | 164701923 | 164710523 | 164751723 | 164751723 | 164751723 | 164756423 | 164756423 | 164756423 | 164756423 | 164756423 | 164959682 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Gland Pharma International Pte Ltd. | Wholly Owned Subsidiary | Investment, Sale of goods or services | 4,827,930,000.00 | 2 |
| Fosun Pharma USA Inc. | Fellow subsidiary | Any other transaction, Sale of goods or services | 994,580,000.00 | 2 |
| Wanbang Biopharmaceutical Company Limited | Fellow subsidiary | Purchase of goods or services | 523,780,000.00 | 1 |
| Srinivas Sadu | Key management personnel | Remuneration | 40,890,000.00 | 2 |
| Avanc Pharma Distribution Co Ltd | Fellow subsidiary | Sale of goods or services | 14,400,000.00 | 1 |
| Ravi Shekhar Mitra | Key management personnel | Remuneration | 11,990,000.00 | 2 |
| Gland Pharma USA INC. | Step down Subsidiary | Any other transaction | 7,330,000.00 | 1 |
| Nainalal Kidwai | Director | Any other transaction | 5,500,000.00 | 2 |
| Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Fellow subsidiary | Purchase of goods or services | 5,200,000.00 | 1 |
| P. Sampath Kumar | Key management personnel | Remuneration | 3,840,000.00 | 1 |
| Satyanarayana Murthy Chavali | Director | Any other transaction | 2,150,000.00 | 2 |
| Udo J. Vetter | Director | Any other transaction | 1,950,000.00 | 2 |
| Essaji Goolam Vahanvati | Director | Any other transaction | 1,950,000.00 | 2 |
| Yiu Kwan Stanley Lau | Director | Any other transaction | 300,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-17 | Q1FY27 | GLAND, GLAND PHARMA LIMITED, |GLAND| | Read the call |
| 2026-05-20 | Q4FY26 | GLAND, GLAND PHARMA LIMITED, OFFICER - CENEXI, OFFICER – CENEXI, |GLAND| | Read the call |
| 2026-02-03 | Q3FY26 | - GLAND PHARMA LIMITED, GLAND PHARMA LIMITED, January 28, 2026, OFFICER - CENEXI, OFFICER | Read the call |
| 2025-11-07 | Q2FY26 | - GLAND PHARMA LIMITED, -- GLAND PHARMA LIMITED, GLAND PHARMA LIMITED, November 03, 2025, | Read the call |
| 2025-08-11 | Q1FY26 | - GLAND PHARMA LIMITED, -- GLAND PHARMA LIMITED, August 05, 2025, GLAND PHARMA LIMITED | Read the call |
| 2025-05-27 | Q4FY25 | GLAND PHARMA LIMITED, OFFICER, CENEXI, OFFICER, GLAND PHARMA LIMITED | Read the call |
| 2025-02-10 | Q3FY25 | - GLAND PHARMA LIMITED, -- GLAND PHARMA LIMITED, February 03, 2025, GLAND PHARMA LIMITED, | Read the call |
| 2024-11-11 | Q2FY25 | Read the call | |
| 2024-08-12 | Q1FY25 | GLAND PHARMA LIMITED | Read the call |
| 2024-05-29 | Q4FY24 | GLAND | Read the call |
| 2024-02-21 | Q3FY24 | GLAND | Read the call |
| 2023-08-11 | Q1FY24 | CHIEF EXECUTIVE OFFICER, OFFICER | Read the call |
| 2023-05-25 | Q4FY23 | CHIEF EXECUTIVE OFFICER, OFFICER | Read the call |
| 2023-01-31 | Q3FY23 | CHIEF EXECUTIVE OFFICER, GLAND, OFFICER | Read the call |
| 2022-11-02 | Q2FY23 | EXECUTIVE OFFICER, GLAND, OFFICER, SUMANTA, VICE | Read the call |
| 2022-07-27 | Q1FY23 | Read the call | |
| 2022-05-26 | Q4FY22 | Read the call | |
| 2022-01-28 | Q3FY22 | & INVESTOR RELATIONS, EXECUTIVE OFFICER, OFFICER | Read the call |
| 2021-11-03 | Q2FY22 | EXECUTIVE OFFICER, INVESTOR RELATIONS, OFFICER | Read the call |
| 2021-07-31 | Q1FY22 | EXECUTIVE OFFICER, INVESTOR RELATION, OFFICER | Read the call |
| 2021-05-21 | Q4FY21 | Read the call | |
| 2021-02-10 | Q3FY21 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY25 | Q3FY26 | Q4FY21 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | The total capex spend during the quarter was INR1,379 million spent at Gland’s Indian sites and at Cenexi. | Over the next 5 years, we plan to invest approximately INR2,000 crores in capex, primarily towards BFS and ophthalmic lines as well as capex towards C… | Lastly on the operational cost side, the kind of capex which we are doing, so the rate of increase of the operational cost over the next two years in … | My last question if I may, what is the CAPEX plan for the next 3 years and in terms of, if you could specify which lines you will be investing in? | Total capex incurred during the financial year ended March 31, 2023, was INR2,230 million, used for increasing API and formulation capacities. | We invested INR3,975 million in capital expenditures during the current fiscal year. | Total CAPEX during the quarter amounted to INR 886 million and full year FY'25 amounted to INR 3,938 million allocated to Gland’s Indian sites and Cen… | We continue to focus on capability building by exploring in-licensing opportunities in the areas of differentiated therapy areas or drug delivery syst… |
| Capital allocation | Third, U.S. market expansion, new customer acquisition and value expansion from the current partners will be the crucial for our growth in the U.S. An… | Because that's how when you make an acquisition, we just don't look at single business. | Just one simple bookkeeping question with acquisition that we have made, could you just provide some broad contours in terms of the cost and I think i… | Sir, in your opening comments, you mentioned something about an inorganic acquisition or that some cost that was spent, so can you highlight something… | We have formally closed the acquisition of Cenexi and welcome it to be a part of the Gland-Fosun family. | This robust performance, coupled with the successful integration of consolidated revenue from our recent acquisition of Cenexi, has propelled our tota… | We recognize that the acquisition thesis has taken longer than expected to fructify, but our strategy to achieve robust growth and profitability remai… | So there are several reasons why we did this acquisition. |
| Costs | Can you explain, at a macro level, China does control a lot of capacity in terms of the raw materials as such. | Our cost savings initiatives include yield improvement, alternate vendor development, alternative energy sourcing, enhanced line efficiencies, operati… | — | Just on the part that you mentioned at the start of the call about the shortages, which you see, I am just curious to understand the reasons which are… | Second question is just on the supply of your raw materials and stoppers for individuals. | — | — | So most of our raw material which we import is open and as well as the revenue is open. |
| Debt and cash | Cash flow from operations during the 9M was INR5,889 million and working capital stood at INR23,060 million as of December 31, 2024. | Selective and disciplined capital deployment will ensure strong ROCE, healthy cash generation and effective working capital management. | Sir, my question is on the working capital as you had earlier said that this will increase in the year inventory days, I mean going forward what shoul… | — | We have generated INR3,640 million of cash flow from operations in FY '23. | During the 12 months ended March 31, 2024, we generated INR9,968 million in cash flow from operations. | Working capital as of March 31st, 2025, was INR 21,683 million. | Cash flow from operations remained healthy at INR4,045 million for Q4 and INR10,314 million for FY '26 compared to INR9,147 million in FY '25, reflect… |
| Demand | In 9M FY '25, we filed 3 RTU infusion bag products with 10 more in the pipeline. | Beyond cartridges and GLP-1s, our pipeline of complex products including harmones suspensions, peptides, RTU bags, co-development programs, biosimilar… | The inventory for the year end has gone up a bit and this is how when we restock our critical inventory for new launches and the increased demand for … | Still, we are not in stage where the pipeline is dry for our partners, so but there is a backlog of orders for us. | We maintained inventory of raw materials and packed materials to be able to cater to the demand. | That should have stabilized as you said, initially, there will be a higher offtake because they also fill the pipeline. | On the demand side, our priorities include • enhancing our footprint and launching new products in high value, high growth ROW markets, • leveraging o… | We are putting new capacities in our sites to cater to improved demand of our existing products and planned new launches. |
| Guidance | We expect commercialization to begin from FY '27. | On Cenexi turnaround update, Cenexi delivered revenues of EUR 50 million and EBITDA of EUR 1 million during the quarter, in line with our guidance. | Although I cannot give exact timeline but the guidance what we are getting is probably two products in Q3 or Q4 of this year will get our first approv… | I mean, can we expect some kind of retrieve in terms of some kind of price increase and some kind of normalization and basically no margins increasing… | And also, in terms of the broad revenue guidance, in terms of the fact that we will also be acquiring you will also be integrating an asset. | How should we think about Cenexi EBITDA for next fiscal and the year after that and I just want to understand what’s the mid- to long-term timeline me… | With innovation, collaboration, and excellence of our guiding principle, I am encouraged by our progress and also optimistic about Gland's trajectory. | At the same time, we expect EBITDA margins to remain strong. |
| Margin | However, gross margin improved 77%, GLAND | Sustained base margins are supported by process optimization in alternate API sourcing, portfolio rationalization, focusing on higher-margin products,… | Just wanted to check, if I adjust for it, your profitability the gross margin is actually improved on a year-on-year basis despite a significant chang… | The companies do have the pipeline, but it did impact in terms of export last quarter and indirectly, it is also impacting the cost, because we are ai… | Gross margin of the company improved during the quarter as compared to same quarter previous year. | Our gross margin for Q4 FY'24 reached 61%, a notable improvement from the 54% recorded in Q4 FY'23. | Encouragingly our gross margin improved to 79% from 77% in the prior quarter. | Adjusted EBITDA came in at INR16,826 million, with margins of 26%, while adjusted PAT stood at INR10,455 million, with margins of 16%. |
| People | — | This performance reflects disciplined execution over the past year, including higher capacity utilization, contract renegotiations, workflow rationali… | — | So, the annualized basis if you see, the increment is normal as what we have been seeing and Mr. Sadu said, there is a headcount increase, so yearly b… | Employee costs have increased by 9% in Q4 FY '23 and 19% in full year FY '23, largely due to additional headcount to support the new production lines … | It's been while since we had acquired this unit, what steps we have taken to ramp up our position in this space and how we can improve the utilization… | While operations at Herouville remain below breakeven due to suboptimal utilization, we have several ongoing tech transfer projects in development tha… | This performance reflects disciplined execution throughout the year, driven by higher capacity utilization, contract renegotiations to account for inf… |
| Pricing | And in terms of pricing or any of the other on the base business, excluding Enoxa and other, has there been an erosion? | These measures typically deliver savings of 1 to 2 percentage points, helping offset any pricing pressure or product mix impact. | So, our pricing and supply is with RDIF. | And just that while we are on this, is this nature you explain that it would take a quarter or so for this to resolve, but in this case, are there opt… | Not just we have grown a number of units have grown, but in some market, the pricing is lower. | I think the pricing wise it's kind of stabilized. | May 20, 2025 the existing products have made as far as the volume growth is concerned, as well as the new launchers, and how the pricing have behaved? | — |
| Revenue growth | Revenue of our base business, ex-Cenexi, while it showed growth of 3% in 9M FY '25 driven by our increased performance in the U.S. market, it decrease… | This translates in to focus on capex and Brownfield expenses to build differentiated capabilities, R&D investments to strengthen the product pipeline,… | — | It is too early, but because the base is high, so the percentage growth will not be same, but if you look at globally, we are trying to get at least 1… | Our full year FY '23 revenue stood at INR36,246 million, a de-growth of 18% over FY '22. | So, the initial focus now is how to make it more efficient line so that we also will increase that we can make more supplies then the top line increas… | So, what should drive the growth of the ROW business for us given that the Saudi contract is not coming? | May 15, 2026 For the full year FY '26, our revenue stood at INR64,307 million, registering a growth of 14.5%. |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2024-08-12 | Q1FY25 | GLAND PHARMA LIMITED | August 06, 2024 at 29% in Q1 FY25; with the active measures taken at Cenexi, we expect our consolidated margins to improve as Cenexi's turnaround progresses. |
| 2025-02-10 | Q3FY25 | February 03, 2025 | So Q3, we estimate that would be a time where we expect the top line to touch 50 million or more and then have EBITDA breakeven. |
| 2025-02-10 | Q3FY25 | February 03, 2025 | So Q3, we estimate that would be a time where we expect the top line to touch 50 million or more and then have EBITDA breakeven. |
| 2026-05-20 | Q4FY26 | GLAND PHARMA LIMITED | May 15, 2026 you think that your guidance of 12% to 13% is a bit conservative because then essentially, what we are implying is that the constant currency growth would only be again high single digits? |
| 2026-05-20 | Q4FY26 | GLAND PHARMA LIMITED | May 15, 2026 you think that your guidance of 12% to 13% is a bit conservative because then essentially, what we are implying is that the constant currency growth would only be again high single digits? |